Bank of America reduced its price target for the company from $32 to $29 and maintained an Underperform rating, citing concerns about consensus expectations. The stock price recently declined 6.8% after Amazon Pharmacy announced it would offer Novo Nordisk's Wegovy weight-loss pill, directly competing in a key growth segment. This raises questions about the differentiation and resilience of the company's telehealth platform beyond its own GLP-1 offerings. The stock closed at $32.34 in the most recent session.